You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameStreptozocin
Accession NumberDB00428  (APRD00209)
TypeSmall Molecule
GroupsApproved
DescriptionAn antibiotic that is produced by Stretomyces achromogenes. It is used as an antineoplastic agent and to induce diabetes in experimental animals. [PubChem]
Structure
Thumb
Synonyms
2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose
2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose
Estreptozocina
N-D-Glucosyl-(2)-n'-nitrosomethylurea
N-D-Glucosyl-(2)-n'-nitrosomethylharnstoff
Streptozocin
Streptozocine
Streptozocinium
Streptozocinum
Streptozotocin
Zanosar
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Zanosarpowder, for solution100 mg/mLintravenousTeva Parenteral Medicines, Inc.2003-12-03Not applicableUs
Zanosar Sterile Powderpowder for solution1 gintravenousPaladin Labs Inc1985-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII5W494URQ81
CAS number18883-66-4
WeightAverage: 265.2206
Monoisotopic: 265.090999849
Chemical FormulaC8H15N3O7
InChI KeyInChIKey=ZSJLQEPLLKMAKR-GKHCUFPYSA-N
InChI
InChI=1S/C8H15N3O7/c1-11(10-17)8(16)9-4-6(14)5(13)3(2-12)18-7(4)15/h3-7,12-15H,2H2,1H3,(H,9,16)/t3-,4-,5-,6-,7+/m1/s1
IUPAC Name
3-methyl-3-nitroso-1-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
SMILES
CN(N=O)C(=O)N[[email protected]]1[C@@H](O)O[[email protected]](CO)[C@@H](O)[C@@H]1O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amino sugars. These are sugars having one alcoholic hydroxy group replaced by an amino group; systematically known as x-amino-x-deoxymonosaccharides. These compounds do not include Glycosylamines.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassAminosaccharides
Direct ParentAmino sugars
Alternative Parents
Substituents
  • Glucosamine
  • Amino sugar
  • N-methylnitrosourea
  • Oxane
  • Nitrosourea
  • Monosaccharide
  • Nitrosamide
  • Semicarbazide
  • Organic nitrosamine
  • Secondary alcohol
  • Polyol
  • N-nitroso compound
  • Hemiacetal
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Hydrocarbon derivative
  • Primary alcohol
  • Organonitrogen compound
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of malignant neoplasms of pancreas (metastatic islet cell carcinoma).
PharmacodynamicsStreptozocin is an antitumour antibiotic consisting of a nitrosourea moiety interposed between a methyl group and a glucosamine. Streptozocin is indicated in the treatment of metastatic islet cell carcinoma of the pancreas. Streptozocin inhibits DNA synthesis in bacterial and mammalian cells. In bacterial cells, a specific interaction with cytosine moieties leads to degradation of DNA. The biochemical mechanism leading to mammalian cell death has not been definitely established; streptozocin inhibits cell proliferation at a considerably lower level than that needed to inhibit precursor incorporation into DNA or to inhibit several of the enzymes involved in DNA synthesis. Although streptozocin inhibits the progression of cells into mitosis, no specific phase of the cell cycle is particularly sensitive to its lethal effects.
Mechanism of actionAlthough its mechanism of action is not completely clear, streptozocin is known to inhibit DNA synthesis, interfere with biochemical reactions of NAD and NADH, and inhibit some enzymes involved in gluconeogenesis. Its activity appears to occur as a result of formation of methylcarbonium ions, which alkylate or bind with many intracellular molecular structures including nucleic acids. Its cytotoxic action is probably due to cross-linking of strands of DNA, resulting in inhibition of DNA synthesis.
Related Articles
AbsorptionPoor oral absorption (17-25%)
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Primarily hepatic

Route of eliminationAs much as 20% of the drug (or metabolites containing an N-nitrosourea group) is metabolized and/or excreted by the kidney.
Half life5-15 minutes
ClearanceNot Available
ToxicitySymptoms of overdose include nausea and vomiting, anorexia, myelosuppression; and nephrotoxicity.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8406
Blood Brain Barrier-0.9659
Caco-2 permeable-0.6495
P-glycoprotein substrateNon-substrate0.6244
P-glycoprotein inhibitor INon-inhibitor0.7667
P-glycoprotein inhibitor IINon-inhibitor0.9787
Renal organic cation transporterNon-inhibitor0.9509
CYP450 2C9 substrateNon-substrate0.6998
CYP450 2D6 substrateNon-substrate0.846
CYP450 3A4 substrateNon-substrate0.5462
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9636
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9893
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9182
BiodegradationReady biodegradable0.7191
Rat acute toxicity2.6715 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.793
hERG inhibition (predictor II)Non-inhibitor0.9288
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Teva parenteral medicines inc
Packagers
Dosage forms
FormRouteStrength
Powder, for solutionintravenous100 mg/mL
Powder for solutionintravenous1 g
Prices
Unit descriptionCostUnit
Zanosar 1 gm powder vial78.82USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point115 °CPhysProp
water solubility5070 mg/LNot Available
logP-1.45HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility33.5 mg/mLALOGPS
logP-1.7ALOGPS
logP-2.7ChemAxon
logS-0.9ALOGPS
pKa (Strongest Acidic)11.43ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area151.92 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity55.96 m3·mol-1ChemAxon
Polarizability23.74 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Brentjens R, Saltz L: Islet cell tumors of the pancreas: the medical oncologist's perspective. Surg Clin North Am. 2001 Jun;81(3):527-42. [PubMed:11459269 ]
  2. Wang Z, Gleichmann H: GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes. 1998 Jan;47(1):50-6. [PubMed:9421374 ]
  3. Schnedl WJ, Ferber S, Johnson JH, Newgard CB: STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994 Nov;43(11):1326-33. [PubMed:7926307 ]
  4. VAVRA JJ, DEBOER C, DIETZ A, HANKA LJ, SOKOLSKI WT: Streptozotocin, a new antibacterial antibiotic. Antibiot Annu. 1959-1960;7:230-5. [PubMed:13841501 ]
  5. Mansford KR, Opie L: Comparison of metabolic abnormalities in diabetes mellitus induced by streptozotocin or by alloxan. Lancet. 1968 Mar 30;1(7544):670-1. [PubMed:4170654 ]
  6. Link [Link]
External Links
ATC CodesL01AD04
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (76.6 KB)
Interactions
Drug Interactions
Drug
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Streptozocin.
AceclofenacAceclofenac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Streptozocin.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Streptozocin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Streptozocin.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Streptozocin.
AdapaleneAdapalene may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Streptozocin.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Streptozocin.
Alendronic acidStreptozocin may increase the hypocalcemic activities of Alendronic acid.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Streptozocin.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Streptozocin.
AmdinocillinThe serum concentration of Streptozocin can be decreased when it is combined with Amdinocillin.
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Streptozocin.
AmoxicillinThe serum concentration of Streptozocin can be decreased when it is combined with Amoxicillin.
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Streptozocin.
AmpicillinThe serum concentration of Streptozocin can be decreased when it is combined with Ampicillin.
AntipyrineAntipyrine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Streptozocin.
ApremilastApremilast may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Streptozocin.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Streptozocin.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Streptozocin.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Streptozocin.
AzapropazoneAzapropazone may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
AzelastineAzelastine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
AzlocillinThe serum concentration of Streptozocin can be decreased when it is combined with Azlocillin.
BalsalazideBalsalazide may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
BenoxaprofenBenoxaprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Benzathine benzylpenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Benzathine benzylpenicillin.
BenzylpenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Benzylpenicillin.
Benzylpenicillin PotassiumThe serum concentration of Streptozocin can be decreased when it is combined with Benzylpenicillin Potassium.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Streptozocin.
BevacizumabBevacizumab may increase the cardiotoxic activities of Streptozocin.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Streptozocin.
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Streptozocin.
Botulinum Toxin Type AStreptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.
Botulinum Toxin Type BStreptozocin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Streptozocin.
BromfenacBromfenac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Streptozocin.
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Streptozocin.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Streptozocin.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Streptozocin.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Streptozocin.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Streptozocin.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Streptozocin.
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Streptozocin.
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Streptozocin.
CarbenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Carbenicillin.
CarboplatinStreptozocin may increase the ototoxic activities of Carboplatin.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Streptozocin.
CarprofenCarprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
CastanospermineCastanospermine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
CelecoxibCelecoxib may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Streptozocin.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Streptozocin.
ChloroquineChloroquine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Streptozocin.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Streptozocin.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Streptozocin.
CisplatinCisplatin may increase the nephrotoxic activities of Streptozocin.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Streptozocin.
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Streptozocin.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Streptozocin.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Streptozocin.
ClodronateStreptozocin may increase the hypocalcemic activities of Clodronate.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Streptozocin.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Streptozocin.
ClonixinClonixin may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Streptozocin.
CloxacillinThe serum concentration of Streptozocin can be decreased when it is combined with Cloxacillin.
ClozapineThe risk or severity of adverse effects can be increased when Streptozocin is combined with Clozapine.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Streptozocin.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Streptozocin.
ColistimethateStreptozocin may increase the nephrotoxic activities of Colistimethate.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Streptozocin.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Streptozocin.
CyclacillinThe serum concentration of Streptozocin can be decreased when it is combined with Cyclacillin.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Streptozocin.
CyclosporineStreptozocin may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneD-Limonene may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Streptozocin.
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Streptozocin.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Streptozocin.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Streptozocin.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Streptozocin.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Streptozocin.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Streptozocin.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Streptozocin.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Streptozocin.
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Streptozocin.
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Streptozocin.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Streptozocin.
DiclofenacDiclofenac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
DicloxacillinThe serum concentration of Streptozocin can be decreased when it is combined with Dicloxacillin.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Streptozocin.
DiflunisalDiflunisal may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Streptozocin.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Streptozocin.
DigoxinDigoxin may decrease the cardiotoxic activities of Streptozocin.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Streptozocin.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Streptozocin.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Streptozocin.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Streptozocin.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Streptozocin.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Streptozocin.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Streptozocin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Streptozocin.
DroxicamDroxicam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Streptozocin.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Streptozocin.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Streptozocin.
EpirizoleEpirizole may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Streptozocin.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Streptozocin.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Streptozocin.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Streptozocin.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Streptozocin.
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Streptozocin.
EtanerceptEtanercept may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Streptozocin.
Etidronic acidStreptozocin may increase the hypocalcemic activities of Etidronic acid.
EtodolacEtodolac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
EtofenamateEtofenamate may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Streptozocin.
EtoricoxibEtoricoxib may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Evening primrose oilEvening primrose oil may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
exisulindexisulind may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Streptozocin.
FenbufenFenbufen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
FenoprofenFenoprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Streptozocin.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Streptozocin.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Streptozocin.
FingolimodStreptozocin may increase the immunosuppressive activities of Fingolimod.
FloctafenineFloctafenine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
FlucloxacillinThe serum concentration of Streptozocin can be decreased when it is combined with Flucloxacillin.
FlunixinFlunixin may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
FlurbiprofenFlurbiprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Streptozocin.
FoscarnetFoscarnet may increase the nephrotoxic activities of Streptozocin.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Streptozocin.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Streptozocin.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Streptozocin.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Streptozocin.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Streptozocin.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Streptozocin.
HMPL-004HMPL-004 may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Streptozocin.
IbandronateStreptozocin may increase the hypocalcemic activities of Ibandronate.
IbuprofenIbuprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Streptozocin.
IbuproxamIbuproxam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
IcatibantIcatibant may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Streptozocin.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Streptozocin.
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Streptozocin.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Streptozocin.
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Streptozocin.
IndomethacinIndomethacin may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Streptozocin.
IndoprofenIndoprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Streptozocin.
IsoxicamIsoxicam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Streptozocin.
KebuzoneKebuzone may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Streptozocin.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Streptozocin.
KetoprofenKetoprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
KetorolacKetorolac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Streptozocin.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Streptozocin.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Streptozocin.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Streptozocin.
LeflunomideThe risk or severity of adverse effects can be increased when Streptozocin is combined with Leflunomide.
LeflunomideLeflunomide may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Streptozocin.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Streptozocin.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Streptozocin.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Streptozocin.
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Streptozocin.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Streptozocin.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Streptozocin.
LornoxicamLornoxicam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Streptozocin.
LoxoprofenLoxoprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
LumiracoxibLumiracoxib may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
MannitolMannitol may increase the nephrotoxic activities of Streptozocin.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Streptozocin.
MasoprocolMasoprocol may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
MecamylamineStreptozocin may increase the neuromuscular blocking activities of Mecamylamine.
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Mefenamic acidMefenamic acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
MeloxicamMeloxicam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
MesalazineMesalazine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Streptozocin.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Streptozocin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Streptozocin.
MeticillinThe serum concentration of Streptozocin can be decreased when it is combined with Meticillin.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Streptozocin.
MezlocillinThe serum concentration of Streptozocin can be decreased when it is combined with Mezlocillin.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Streptozocin.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Streptozocin.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Streptozocin.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Streptozocin.
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Streptozocin.
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
NabumetoneNabumetone may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Streptozocin.
NafcillinThe serum concentration of Streptozocin can be decreased when it is combined with Nafcillin.
NaftifineNaftifine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Streptozocin.
NaproxenNaproxen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
NatalizumabThe risk or severity of adverse effects can be increased when Streptozocin is combined with Natalizumab.
NCX 4016NCX 4016 may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Streptozocin.
NepafenacNepafenac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Streptozocin.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Streptozocin.
Niflumic AcidNiflumic Acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Streptozocin.
NimesulideNimesulide may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Streptozocin.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Streptozocin.
OlanzapineThe serum concentration of Olanzapine can be decreased when it is combined with Streptozocin.
OlopatadineOlopatadine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
OlsalazineOlsalazine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Streptozocin.
OrgoteinOrgotein may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Streptozocin.
OuabainOuabain may decrease the cardiotoxic activities of Streptozocin.
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Streptozocin.
OxacillinThe serum concentration of Streptozocin can be decreased when it is combined with Oxacillin.
OxaprozinOxaprozin may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Streptozocin.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Streptozocin.
PamidronateStreptozocin may increase the hypocalcemic activities of Pamidronate.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Streptozocin.
ParecoxibParecoxib may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Streptozocin.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Streptozocin.
PhenoxymethylpenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Phenoxymethylpenicillin.
PhenylbutazonePhenylbutazone may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Streptozocin.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Streptozocin.
PiperacillinThe serum concentration of Streptozocin can be decreased when it is combined with Piperacillin.
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Streptozocin.
PirfenidonePirfenidone may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
PiroxicamPiroxicam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Streptozocin.
PivampicillinThe serum concentration of Streptozocin can be decreased when it is combined with Pivampicillin.
PivmecillinamThe serum concentration of Streptozocin can be decreased when it is combined with Pivmecillinam.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Streptozocin.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Streptozocin.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Streptozocin.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Streptozocin.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Streptozocin.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Streptozocin.
Procaine benzylpenicillinThe serum concentration of Streptozocin can be decreased when it is combined with Procaine benzylpenicillin.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Streptozocin.
PropacetamolPropacetamol may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Streptozocin.
PTC299PTC299 may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Streptozocin.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Streptozocin.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Streptozocin.
Rabies vaccineThe risk or severity of adverse effects can be increased when Streptozocin is combined with Rabies vaccine.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Streptozocin.
ReserpineThe serum concentration of Reserpine can be decreased when it is combined with Streptozocin.
ResveratrolResveratrol may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
RifampicinThe serum concentration of Rifampicin can be decreased when it is combined with Streptozocin.
RisedronateStreptozocin may increase the hypocalcemic activities of Risedronate.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Streptozocin.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Streptozocin.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Streptozocin.
RofecoxibRofecoxib may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
RoflumilastRoflumilast may increase the immunosuppressive activities of Streptozocin.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Streptozocin.
SalicylamideSalicylamide may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Salicylic acidSalicylic acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Streptozocin.
SalsalateSalsalate may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Streptozocin.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Streptozocin.
SeratrodastSeratrodast may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Streptozocin.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Streptozocin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Streptozocin.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Streptozocin.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Streptozocin.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Streptozocin.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Streptozocin.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Streptozocin.
SRT501SRT501 may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulbactamThe serum concentration of Streptozocin can be decreased when it is combined with Sulbactam.
SulfasalazineSulfasalazine may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulindacSulindac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SuprofenSuprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Streptozocin.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Streptozocin.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Streptozocin.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Streptozocin.
Technetium Tc-99m MedronateStreptozocin may increase the hypocalcemic activities of Technetium Tc-99m Medronate.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Streptozocin.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Streptozocin.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Streptozocin.
TenofovirThe serum concentration of Streptozocin can be increased when it is combined with Tenofovir.
TenoxicamTenoxicam may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
TepoxalinTepoxalin may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
TeriflunomideTeriflunomide may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Streptozocin.
TicarcillinThe serum concentration of Streptozocin can be decreased when it is combined with Ticarcillin.
TiludronateStreptozocin may increase the hypocalcemic activities of Tiludronate.
TimololThe serum concentration of Timolol can be decreased when it is combined with Streptozocin.
TofacitinibStreptozocin may increase the immunosuppressive activities of Tofacitinib.
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
TolmetinTolmetin may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Streptozocin.
TopotecanThe serum concentration of Topotecan can be decreased when it is combined with Streptozocin.
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Streptozocin.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Streptozocin.
TranilastTranilast may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
TrastuzumabTrastuzumab may increase the neutropenic activities of Streptozocin.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Streptozocin.
Trisalicylate-cholineTrisalicylate-choline may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Streptozocin.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Streptozocin.
ValdecoxibValdecoxib may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
VancomycinVancomycin may increase the nephrotoxic activities of Streptozocin.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Streptozocin.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Streptozocin.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Streptozocin.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Streptozocin.
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Streptozocin.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Streptozocin.
ZaltoprofenZaltoprofen may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Streptozocin.
ZileutonZileuton may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Zoledronic acidStreptozocin may increase the hypocalcemic activities of Zoledronic acid.
ZomepiracZomepirac may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
Food InteractionsNot Available

Targets

1. DNA
Kind
Nucleotide
Organism
Human
Pharmacological action
yes
Actions
cross-linking/alkylation
General Function:
Used for biological information storage.
Specific Function:
DNA contains the instructions needed for an organism to develop, survive and reproduce.
Molecular Weight:
2.15 x 1012 Da
References
  1. Bennett RA, Pegg AE: Alkylation of DNA in rat tissues following administration of streptozotocin. Cancer Res. 1981 Jul;41(7):2786-90. [PubMed:6454479 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
ligand
General Function:
Hexose transmembrane transporter activity
Specific Function:
Facilitative glucose transporter. This isoform likely mediates the bidirectional transfer of glucose across the plasma membrane of hepatocytes and is responsible for uptake of glucose by the beta cells; may comprise part of the glucose-sensing mechanism of the beta cell. May also participate with the Na(+)/glucose cotransporter in the transcellular transport of glucose in the small intestine an...
Gene Name:
SLC2A2
Uniprot ID:
P11168
Molecular Weight:
57488.955 Da
References
  1. Wang Z, Gleichmann H: GLUT2 in pancreatic islets: crucial target molecule in diabetes induced with multiple low doses of streptozotocin in mice. Diabetes. 1998 Jan;47(1):50-6. [PubMed:9421374 ]
  2. Schnedl WJ, Ferber S, Johnson JH, Newgard CB: STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes. 1994 Nov;43(11):1326-33. [PubMed:7926307 ]
Kind
Protein
Organism
Bacteroides thetaiotaomicron (strain ATCC 29148 / DSM 2079 / NCTC 10582 / E50 / VPI-5482)
Pharmacological action
yes
Actions
antagonist
General Function:
Beta-n-acetylglucosaminidase activity
Specific Function:
Can hydrolyze the glycosidic link of O-GlcNAcylated proteins. Can use p-nitrophenyl-beta-GlcNAc and 4-methylumbelliferone-GlcNAc as substrates (in vitro).
Gene Name:
Not Available
Uniprot ID:
Q89ZI2
Molecular Weight:
84484.62 Da
References
  1. He Y, Martinez-Fleites C, Bubb A, Gloster TM, Davies GJ: Structural insight into the mechanism of streptozotocin inhibition of O-GlcNAcase. Carbohydr Res. 2009 Mar 31;344(5):627-31. doi: 10.1016/j.carres.2008.12.007. Epub 2008 Dec 13. [PubMed:19217614 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Choi YH, Lee AK, Bae SK, Kim SO, Lee MG: Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. Biopharm Drug Dispos. 2005 Apr;26(3):93-8. [PubMed:15674819 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Choi YH, Lee AK, Bae SK, Kim SO, Lee MG: Pharmacokinetics of 5-fluorouracil in rats with diabetes mellitus induced by streptozotocin. Biopharm Drug Dispos. 2005 Apr;26(3):93-8. [PubMed:15674819 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic or carcinogenic forms.
Gene Name:
CYP2E1
Uniprot ID:
P05181
Molecular Weight:
56848.42 Da
References
  1. Kataoka S, Yasui H, Hiromura M, Sakurai H: Effect of insulin-mimetic vanadyl sulfate on cytochrome P450 2E1-dependent p-nitrophenol hydroxylation in the liver microsomes of streptozotocin-induced type 1 diabetic rats. Life Sci. 2005 Oct 14;77(22):2814-29. [PubMed:15964029 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Brady JM, Cherrington NJ, Hartley DP, Buist SC, Li N, Klaassen CD: Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab Dispos. 2002 Jul;30(7):838-44. [PubMed:12065443 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23